Overview

Intravitreal Injections of Melphalan for Retinoblastoma

Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
0
Participant gender:
All
Summary
Retinoblastoma treatment has become more and more focused in the last years. New treatments developed by Dr. Kaneko from Japan in 1995 are now being tested in clinical trials. Intra-arterial chemotherapy with Melphalan has shown success in some patients but with limited response when there is marked vitreal seeding. For these cases Intravitreal injections of Melphalan have been successful in Japan. In this study the same chemotherapy (melphalan) will be administered intravitreally (directly through the eye wall) and the response (short and long term) will be monitored.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hadassah Medical Organization
Treatments:
Melphalan
Criteria
Inclusion Criteria:

- Retinoblastoma that has not responded to chemotherapy

- Retinoblastoma that has vitreal seeding

Exclusion Criteria:

- previous failure of IVit Melphalan